Loading
A phase 3 trial of Durvalumab in endometrial cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain is a phase 3 interventional study registered as NCT06746116 by AstraZeneca, with 45 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2028-11-30. Interventions recorded: Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase. Conditions listed: Advanced or Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/